Is There a Role for Immunotherapy in Prostate Cancer?

In the last decade, immunotherapy has revolutionized the treatment landscape of several hematological and solid malignancies, reporting unprecedented response rates. Unfortunately, this is not the case for metastatic castration-resistant prostate cancer (mCRPC), as several phase I and II trials asse...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cells (Basel, Switzerland) Ročník 9; číslo 9; s. 2051
Hlavní autoři:	Rizzo, Alessandro, Mollica, Veronica, Cimadamore, Alessia, Santoni, Matteo, Scarpelli, Marina, Giunchi, Francesca, Cheng, Liang, Lopez-Beltran, Antonio, Fiorentino, Michelangelo, Montironi, Rodolfo, Massari, Francesco
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland MDPI AG 08.09.2020 MDPI
Témata:	Antibodies Antitumor agents Biomarkers Cancer vaccines Care and treatment Castration Clinical trials CTLA-4 CTLA-4 protein Cytotoxicity FDA approval Humans Immune checkpoint Immunotherapy Immunotherapy - methods Kidney cancer Lymphocytes T Male Malignancy Melanoma Metastases Metastasis Methods Monoclonal antibodies Mutation pd-1 PD-1 protein predictive biomarkers Prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - therapy Radiation therapy Review Skin cancer Tumors Vaccines Italy predictive biomarkers prostate cancer vaccines immunotherapy combination therapy CTLA-4 immune checkpoint inhibitors pd-1
ISSN:	2073-4409, 2073-4409
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!